Elafibranor demonstrates significant anticholestatic effects in the treatment of primary biliary cholangitis
ILC 2019: Phase 2 study reports significant reductions in alkaline phosphatase and high responder rates among individuals with primary biliary cholangitis treated with elafibranor 13 April 2019, Vienna, Austria EASL…
Bulevirtide shows promise in the treatment of chronic hepatitis B/D (HBV/HDV) coinfection
ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high…
SMART-C study suggests simplified monitoring of direct-acting antiviral treatment in hepatitis C is possible
ILC 2019: Randomized controlled study reports favourable virological outcomes with simplified monitoring of glecaprevir/pibrentasvir treatment in chronic hepatitis C infection 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE…
Nivolumab and pembrolizumab display anti-tumour activity and adequate tolerance in ‘real-world’ studies in carcinoma
Nivolumab and pembrolizumab display anti-tumour activity and adequate tolerance in ‘real-world’ studies in carcinoma ILC 2019: ‘Real-world’ studies report the activity and safety profiles of nivolumab and pembrolizumab to be…
Emricasan fails to meet primary endpoint in ENCORE-PH study but shows potential benefits in high-risk individuals
ILC 2019: ENCORE-PH study of emricasan in nonalcoholic steatohepatitis (NASH)-related cirrhosis and severe portal hypertension (PH) fails to meet primary endpoint, but benefits reported in individuals at high risk of…